Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020065584 - METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS

Publication Number WO/2020/065584
Publication Date 02.04.2020
International Application No. PCT/IB2019/058188
International Filing Date 26.09.2019
IPC
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 36/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • PHOSPHOGAM, INC. [US]/[US]
Inventors
  • LOPEZ, Richard D.
Agents
  • BUCK, B. Logan
Priority Data
62/737,37827.09.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS
(FR) PROCÉDÉS ET COMPOSITIONS POUR LA MULTIPLICATION ET L'UTILISATION DE LYMPHOCYTES T GAMMA/DELTA ALLOGÉNIQUES
Abstract
(EN)
Methods for treating cancer in a subject are provided herein. Such methods comprise administration of donor-derived allogeneic γδ-T cells (gamma/delta-T cells) to a subject. In such methods, at least one lymphodepletion treatment or a Hematopoietic Stem Cell (HSC) transplant is administered to the subject, followed by the subsequent administration of donor-derived allogeneic γδ-T cells. The methods also comprise expanding the donor-derived allogeneic γδ-T cells ex vivo prior to administration to the subject. Such methods comprise exposing donor-derived allogeneic γδ-T cells to one or more γδ-T cell expansion compounds. Such a therapy induces an antitumor response in the subject.
(FR)
La présente invention concerne des méthodes de traitement du cancer chez un sujet. Lesdites méthodes comprennent l'administration de lymphocytes T γδ (lymphocytes T gamma/delta) allogéniques provenant d'un donneur à un sujet. Dans lesdites méthodes, au moins un traitement de lymphodéplétion ou une transplantation de cellules souches hématopoïétiques (CSH) est pratiqué sur le sujet, cela étant suivi de l'administration ultérieure de lymphocytes T γδ allogéniques provenant d'un donneur. Les méthodes consistent également à multiplier les lymphocytes T γδ allogéniques provenant d'un donneur ex vivo avant l'administration au sujet. Lesdites méthodes comprennent l'exposition des lymphocytes T γδ allogéniques provenant d'un donneur à un ou plusieurs composés favorisant la multiplication des lymphocytes T γδ. Une telle thérapie induit une réponse antitumorale chez le sujet.
Latest bibliographic data on file with the International Bureau